SANA
Sana Biotechnology, Inc.Healthcare·Biotechnology
$3.30
$918M market cap
Revenue
$0.0M
Free Cash Flow
$-71.2M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute
2-Year Price History
$3.07-59.1%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -35.5 | -37.9 | -47.2 | -37.4 | -37.7 | -0.3 | 101.1 | 75.3 | 276.9 | -177.9% | -- | -- |
| Act | 2025-Q4 | 0.0 | -58.2 | -61.2 | -58.8 | -32.6 | -33.5 | -0.9 | 138.4 | 78.9 | 253.2 | -186.7% | -- | -- |
Valuation & Metrics
Market Stats
Price$3.30
Market Cap$918M
Enterprise Value$893M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-7.8%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-106.0M
Free Cash Flow$-71.2M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-182.3%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares41.1M
Days to Cover13.2
Change (vs Prior)+0.5%
Need at least 2 settlement dates for chart
Employees
Headcount194
Revenue / Employee$0
Gross Profit / Employee$-12,325
Cash Runway
17.1months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
39.8%(+17.4% YoY)
178 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
13.5%(+7.6% YoY)
12 filers
Vanguard, iShares, SPDR
Market makers
0.4%(+0.2% YoY)
9 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| FMR LLC | $108M | $5.86 | +$0 | +$10.6M | -0.0% | $1.89T |
| Flagship Pioneering Inc. | $72.0M | $6.43 | +$0 | +$0 | -13.5% | $1.16B |
| BlackRock, Inc.Passive | $41.0M | $4.11 | +$48K | +$8.0M | -0.2% | $5.69T |
| STATE STREET CORPPassive | $30.3M | $4.16 | +$7.2M | +$14.5M | -0.2% | $2.89T |
| CANADA PENSION PLAN INVESTMENT BOARD | $29.4M | $4.07 | −$58K | +$135K | +0.6% | $155.02B |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $21.4M | $2.88 | +$21.4M | +$21.4M | — | $4.04T |
| BAILLIE GIFFORD & CO | $19.0M | $5.17 | +$0 | −$10.3M | -2.0% | $97.89B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $12.0M | $4.81 | +$184K | +$2.6M | +2.3% | $1.61T |
| Marex Group plc | $11.5M | $2.73 | +$767K | +$11.3M | -1.7% | $9.64B |
| Integral Health Asset Management, LLC | $9.2M | $5.47 | +$576K | +$3.5M | -0.4% | $1.64B |
| GOLDMAN SACHS GROUP INC | $9.2M | $3.89 | +$4.9M | +$7.6M | -0.2% | $760.93B |
| BANK OF AMERICA CORP /DE/ | $8.5M | $3.55 | +$5.1M | +$7.0M | -0.1% | $1.36T |
| Alphabet Inc. | $8.1M | $6.43 | +$0 | +$0 | +0.2% | $4.02B |
| VANGUARD PORTFOLIO MANAGEMENT LLCPassive | $4.9M | $2.88 | +$4.9M | +$4.9M | — | $1.91T |
| MILLENNIUM MANAGEMENT LLC | $4.6M | $3.78 | +$2.8M | +$3.9M | -0.5% | $127.40B |
| NORTHERN TRUST CORPPassive | $4.3M | $3.67 | +$205K | +$517K | -0.2% | $755.34B |
| MORGAN STANLEY | $4.2M | $5.46 | +$504K | +$1.8M | -0.3% | $1.65T |
| RENAISSANCE TECHNOLOGIES LLC | $4.2M | $3.38 | −$691K | +$4.2M | +1.2% | $63.91B |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $3.9M | $4.87 | −$96K | +$864K | +0.7% | $645.81B |
| UBS Group AG | $3.9M | $3.25 | +$496K | +$1.8M | -0.3% | $562.11B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)NEUTRAL
Holders
-2.93%
avg per quarter
Holders (ex-self)
-3.01%
excl. this stock
Buyers (this Q)
-0.14%
48 buyers · $0.05B in
Sellers (this Q)
+0.22%
59 sellers · $0.04B out
alpha coverage: 94% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
-6.6%
how holders react when this stock falls
On quiet Qs
-9.3%
−10% to +10% baseline
On rallies (+10%+)
-0.9%
how they react when this stock rises
Holders' portfolio flow this Q
+42.3%
inflows — adds are organic
Sellers' portfolio flow this Q
+8.4%
Sellers grew AUM elsewhere — opinionated cut of this stock.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-4.9%
Holder mid (any stock)
-2.8%
Holder rally (any stock)
-3.8%
Biggest decreases this quarter
GREAT POINT PARTNERS LLCexited−$2.8MBALYASNY ASSET MANAGEMENT LLC−$1.9Mα-0.4Private Advisor Group, LLCexited−$1.3MDekaBank Deutsche Girozentraleexited−$1.2MTWO SIGMA INVESTMENTS, LP−$1.1Mα-0.9RENAISSANCE TECHNOLOGIES LLC−$691Kα+1.2TD ASSET MANAGEMENT INCexited−$328KVARCOV Co.exited−$264KNewEdge Advisors, LLCexited−$262KBIT Capital GmbHexited−$236K
New buyers this quarter
Top-5 holders · 59.4%
FMR LLC--
Flagship Pioneering Inc.--
BlackRock, Inc.--
STATE STREET CORP--
CANADA PENSION PLAN INVESTMENT BOARD--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
Flagship Pioneering Inc.25.0MBAILLIE GIFFORD & CO6.6MCANADA PENSION PLAN INVESTMENT BOARD10.2MFMR LLC37.4MPUBLIC SECTOR PENSION INVESTMENT BOARD—Crestline Management, LP756KAlphabet Inc.2.8MCapital World Investors—SB Management Ltd—T. Rowe Price Investment Management, Inc.—
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (3 analysts)$8.6716270.0%
Last Year (4 analysts)$8.5015760.0%
Current Price$3.30
Analyst Ratings
9
2
Buy: 9Hold: 2Consensus: Buy
Corporate
Order Flow (FINRA, ~3w lag)
37.3%retail+1.9pp
12.8%dark+2.5pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Sana Biotechnology: A Dilutive Cash Incinerator Skirting a Going Concern Crisis
Overall Risk
8/10
Fraud
3/10
Dilution
9/10
Insolvency
7/10
Earnings Overstated
2/10
Hidden Liabilities
6/10
Legal
4/10
Audit Warnings
8/10
Hidden Upside
4/10
Contextually Acceptable
3/10